The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF 4 and cereblon expression
Open accessAbstract
Summary: Durable responses with lenalidomide monotherapy have been reported in patients with non‐Hodgkin lymphoma. In relapsed/refractory diffuse large B‐cell lymphoma (DLBCL), higher responses were observed in the activated B‐cell‐like (ABC) subtype than in the germinal centre B‐cell‐like subtype. Herein, the molecular mechanisms involved in the differential efficacy of lenalidomide in DLBCL subtypes were investigated. Using DLBCL cell lines, lenalidomide treatment was found to preferentially suppress proliferation of ABC‐DLBCL cells in vitro and delay tumour growth in a human tumour xenograft model, with minimal effect on non‐ABC‐DLBCL cells. This tumouricidal effect was associated with downregulation of interferon regulatory factor 4 (IRF 4), a hallmark of ABC‐DLBCL cells. IRF 4 inhibition by lenalidomide induced downregulation of B‐cell receptor (BCR)‐dependent NF‐κB. Whereas IRF 4‐specific small, interfering RNA mimicked the effects of lenalidomide reducing NF‐κB activation, IRF 4 overexpression enhanced NF‐κB activation and conferred resistance to lenalidomide. These findings indicate the crucial role of IRF 4 inhibition in lenalidomide efficacy in ABC cells. Furthermore, lenalidomide‐induced IRF 4 downregulation required the expression of cereblon, a molecular target of lenalidomide. Taken together, these findings suggest that lenalidomide has direct antitumour activity against DLBCL cells, preferentially ABC‐DLBCL cells, by blocking IRF 4 expression and the BCR‐NF‐κB signalling pathway in a cereblon‐dependent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Novel disease targets and management approaches for diffuse large B-cell lymphoma
Wilson, W. H., Hernandez-Ilizaliturri, F. J., Dunleavy, K., Little, R. F., & O'Connor, O. A. (2010) · Leukemia & Lymphoma · doi:10.3109/10428194.2010.500045 · Cited by 34
Cited by
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
Roschewski, M., Staudt, L. M., & Wilson, W. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.197 · Cited by 411
Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma
Gribben, J. G., Fowler, N., & Morschhauser, F. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5363 · Cited by 296
Nowakowski, G. S., Chiappella, A., Gascoyne, R. D., Scott, D. W., Zhang, Q., Jurczak, W., Özcan, M., Hong, X., Zhu, J., Jin, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01366 · Cited by 275
Metadata
- Authors
- Zhang, L., Kosek, J., Wang, M., Heise, C., Schafer, P. H., & Chopra, R.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2012-12-18
- Volume
- 160
- Issue
- 4
- Pages
- 487-502
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2077848703
- Cited by
- 167
- References
- 3
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.